

# Javier Ampuero

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6382588/javier-ampuero-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96  
papers

1,657  
citations

22  
h-index

37  
g-index

113  
ext. papers

2,315  
ext. citations

4.5  
avg, IF

4.71  
L-index

#	Paper	IF	Citations
96	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	3
95	Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies.. <i>Journal of Clinical and Translational Hepatology</i> , <b>2022</b> , 10, 356-362	5.2	0
94	Long non-coding RNA H19 as biomarker for hepatocellular carcinoma.. <i>Liver International</i> , <b>2022</b> ,	7.9	2
93	Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation.. <i>Scientific Reports</i> , <b>2022</b> , 12, 3418	4.9	1
92	Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.. <i>Journal of Gastroenterology</i> , <b>2022</b> , 57, 357	6.9	1
91	General Overview About the Current Management of Nonalcoholic Fatty Liver Disease.. <i>Clinical Drug Investigation</i> , <b>2022</b> , 1	3.2	0
90	Correction to: A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure.. <i>American Journal of Gastroenterology</i> , <b>2022</b> , 117, 819	0.7	
89	Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 519-530	6.1	2
88	Impact of liver injury on the severity of COVID-19: a systematic review with meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2021</b> , 113, 125-135	0.9	4
87	Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 667354	8.4	1
86	Impact of COVID-19 on liver disease: From the experimental to the clinic perspective.. <i>World Journal of Virology</i> , <b>2021</b> , 10, 301-311	6.9	0
85	An Experimental DUAL Model of Advanced Liver Damage. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1051-1068		2
84	Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 1754-1768	4	2
83	Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1238-1247	0.7	2
82	Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 971-972	13.4	
81	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , <b>2021</b> , 41, 2076-2086	7.9	5
80	Management of NAFLD patients with advanced fibrosis. <i>Liver International</i> , <b>2021</b> , 41 Suppl 1, 95-104	7.9	3

79	Wilson's disease: Revisiting an old friend. <i>World Journal of Hepatology</i> , <b>2021</b> , 13, 634-649	3.4	6
78	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 806-815.e5	6.9	21
77	Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. <i>Clinical and Translational Medicine</i> , <b>2021</b> , 11, e275	5.7	
76	COVID-19 and the liver: the chicken or the egg dilemma. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2021</b> , 113, 555	0.9	
75	Looking for a new name for non-alcoholic fatty liver disease in Spanish: esteatosis hepática metabólica (EHmet). <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2021</b> , 113, 161-163	0.9	2
74	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , <b>2021</b> ,	19.2	27
73	A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. <i>American Journal of Gastroenterology</i> , <b>2021</b> ,	0.7	2
72	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	1
71	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 770-785	13.4	19
70	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 786-794	13.4	21
69	Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients.. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 8343-8356	5.6	0
68	Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes. <i>Gut</i> , <b>2021</b> ,	19.2	2
67	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , <b>2020</b> , 40, 2182-2193	7.9	6
66	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 17-25	13.4	26
65	COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2020</b> , 112, 389-396	0.9	13
64	Morbid obesity and hepatitis C: treat as normal or are there additional issues to consider? <b>2020</b> , 59-65		
63	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. <i>Polish Archives of Internal Medicine</i> , <b>2020</b> , 130, 975-985	1.9	3
62	Reflex testing. A key tool for the elimination of hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2020</b> , 112, 513-514	0.9	

61 The Spectrum of NAFLD: From the Organ to the System **2020**, 1-10

60	Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy. <i>Liver International</i> , <b>2020</b> , 40, 921-930	7.9	2
59	Hepatitis C Virus Clearance by Direct-Acting Antiviral Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00203	4.2	9
58	Stratification of patients in NASH clinical trials: A pitfall for trial success. <i>JHEP Reports</i> , <b>2020</b> , 2, 100148	10.3	9
57	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 216-225.e5	6.9	46
56	Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 660-665	13.4	50
55	Usefulness of bioelectrical impedance analysis for monitoring patients with refractory ascites. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2019</b> , 111, 223-227	0.9	2
54	Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2019</b> , 111, 301-307	0.9	2
53	Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2019</b> , 111, 270-274	0.9	2
52	Quality of life in patients with hepatitis C. Importance of treatment. <i>Gastroenterología Y Hepatología</i> , <b>2019</b> , 42 Suppl 1, 20-25	0.9	0
51	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1495-1502	6.9	55
50	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 940-948	13.4	12
49	Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. <i>Therapeutic Advances in Gastroenterology</i> , <b>2018</b> , 11, 1756283X17743419	4.7	8
48	Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: A meta-analysis. <i>Liver International</i> , <b>2018</b> , 38, 1820-1831	7.9	11
47	New therapeutic perspectives in non-alcoholic steatohepatitis. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 128-142	0.9	8
46	miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 1335-1348	13.4	73
45	Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191805	3.7	18
44	Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2018</b> , 110, 427-433	0.9	3

43	Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 718-725	4	24
42	Peer-to-Peer Sessions in Primary Care to Improve the Hepatitis B Detection Rate in Seville, Spain. <i>Annals of Hepatology</i> , <b>2018</b> , 17, 864-870	3.1	0
41	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1260-1270	6.1	43
40	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 945-949.e1	6.9	18
39	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1138-1148	13.4	131
38	Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 304-311	3.4	33
37	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir + dasabuvir + ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 226-237	3.4	17
36	Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. <i>Liver International</i> , <b>2017</b> , 37, 212-223	7.9	17
35	Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. <i>World Journal of Hepatology</i> , <b>2017</b> , 9, 697-703	3.4	8
34	Acute-on-chronic liver failure: a time to step forward. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2017</b> , 109, 397-398	0.9	0
33	Pharmacogenetics of ribavirin-induced anemia in hepatitis C. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1587-94	2.6	7
32	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 31421	4.9	22
31	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 390-398	13.4	55
30	Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 5285-92	5.6	8
29	Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 10064-10070	5.6	15
28	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1611-8	4	17
27	Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis. <i>Seminars in Liver Disease</i> , <b>2016</b> , 36, 181-6	7.3	2
26	New technologies - new insights into the pathogenesis of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , <b>2016</b> , 31, 1259-1267	3.9	7

25	Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. <i>Clinical Microbiology and Infection</i> , <b>2016</b> , 22, 839-845	9.5	25
24	Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 112-8	4	9
23	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , <b>2015</b> , 68, 56-60	14.5	9
22	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. <i>Genes and Immunity</i> , <b>2015</b> , 16, 297-300	4.4	8
21	Interferon- $\gamma$ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , <b>2015</b> , 6, 6422	17.4	127
20	Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis. <i>Gastroenterology</i> , <b>2015</b> , 149, 1483-9	13.3	80
19	Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3. <i>Gastroenterology Clinics of North America</i> , <b>2015</b> , 44, 845-57	4.4	13
18	Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 1105-11	3.4	25
17	Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122613	3.7	1
16	Assessing cardiovascular risk in hepatitis C: An unmet need. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 2214-9	3.4	21
15	The Oral Glutamine Challenge in Liver Cirrhosis <b>2015</b> , 229-236		
14	Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2015</b> , 107, 10-6	0.9	52
13	Stanozolol-induced bland cholestasis. <i>Gastroenterología Y Hepatología</i> , <b>2014</b> , 37, 71-2	0.9	8
12	P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV). <i>Journal of Hepatology</i> , <b>2014</b> , 60, S139	13.4	2
11	Review article: HCV genotype 3 - the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 686-98	6.1	93
10	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 356-363	3.1	15
9	Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 291-5	4	23
8	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 356-63	3.1	12

7	Role of diabetes mellitus on hepatic encephalopathy. <i>Metabolic Brain Disease</i> , <b>2013</b> , 28, 277-9	3.9	25
6	Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 74-80	6.1	16
5	Meta-analysis: pegylated interferon $\alpha$ -2a achieves higher early virological responses than $\alpha$ -2b in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 1065-73	6.1	6
4	Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 7327-40	5.6	77
3	Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 420-430	3.1	18
2	Re: Unsedated colonoscopy: an option for some but not for all. <i>Gastrointestinal Endoscopy</i> , <b>2012</b> , 76, 699; author reply 699	5.2	1
1	Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. <i>PLoS ONE</i> , <b>2012</b> , 7, e49279	3.7	42